High-rolling investors have positioned themselves bullish on Biogen (NASDAQ:BIIB), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...
So how do we know what these investors just did? Today, Benzinga's options scanner spotted 9 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders ...
Hosted on MSN1mon
Biogen Gears Up to Report Q4 Earnings: What's in the Cards?Our proven model does not conclusively predict an earnings beat for Biogen this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold ...
Biogen Inc. (BIIB) closed at $216.69 in the latest trading session, marking a -0.65% move from the prior day. This change lagged the S&P 500's daily loss of 0.31%. Elsewhere, the Dow lost 0.41% ...
So how do we know what these investors just did? Today, Benzinga's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money ...
What risks does Biogen face from increasing competition in its key markets? Biogen operates in highly competitive markets, particularly in neuroscience and rare diseases. In the Alzheimer's space, the ...
2025 Non-GAAP Diluted EPS Guidance: Between $15.25 and $16.25. Biogen Inc (NASDAQ:BIIB) launched four first-in-class, disease-modifying products in Alzheimer's, Friedreich's ataxia, depression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback